Ischaemic Stroke Temporally Associated with Oral Tranexamic Acid Therapy for Melasma: A Case Report
Case Reports in Dermatology · 13.11.2026
DOI: 10.1159/cde/abvag040 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Dermatology, online erschienen am 13.11.2026. Verfasst von Sabriya Abdeen und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
We report a 40-year-old woman with treated hypertension who developed bilateral internal carotid artery dissections and acute right middle cerebral artery infarction three weeks after commencing oral tranexamic acid (TXA) 500 mg daily for melasma. Treatment comprised dual antiplatelet therapy and modification of vascular risk factors; thrombolysis was not administered. Oral TXA was discontinued, and her neurological deficits had resolved within 24 hours. As the dissections alone could account for the infarction, a causal role for TXA cannot be established, although a contributory effect through impaired fibrinolysis at the site of arterial injury is plausible. To our knowledge, this is the first reported case of ischaemic stroke temporally associated with oral TXA prescribed for a dermatological indication. The case supports comprehensive vascular risk assessment, including arterial risk factors, prior to prescribing.
Zitieren
APA
Abdeen, S., Shao, E., & Lim, D. (2026). Ischaemic Stroke Temporally Associated with Oral Tranexamic Acid Therapy for Melasma: A Case Report. Case Reports in Dermatology. https://doi.org/10.1159/cde/abvag040
Vancouver
Abdeen S, Shao E, Lim D. Ischaemic Stroke Temporally Associated with Oral Tranexamic Acid Therapy for Melasma: A Case Report. Case Reports in Dermatology. 2026. doi:10.1159/cde/abvag040
BibTeX
@article{Abdeen2026,
author = {Abdeen, Sabriya and Shao, Emily and Lim, Davin},
title = {Ischaemic Stroke Temporally Associated with Oral Tranexamic Acid Therapy for Melasma: A Case Report},
journal = {Case Reports in Dermatology},
year = {2026},
doi = {10.1159/cde/abvag040}
}
EUVIMED